The C1orf159 Knockout HeLa Polyclonal Cells are a CRISPR/Cas9-edited polyclonal cell population with targeted disruption of the C1orf159 gene, a poorly characterized protein-coding locus. This knockout model enables loss-of-function studies to elucidate the cellular roles of C1orf159. As a polyclonal population, it contains a heterogeneous mix of edited alleles, avoiding clonal selection biases and providing a physiologically relevant platform for functional genomics. The product is generated via CRISPR/Cas9 ribonucleoprotein delivery to achieve high-efficiency gene disruption, making it suitable for initial phenotype discovery and screening applications.
The host HeLa cell line is an epithelial model derived from cervical adenocarcinoma. HeLa cells are HPV18-positive and express the viral oncoproteins E6 and E7, which degrade p53 and inactivate Rb, respectively, thereby abrogating key tumor suppressor pathways. Additionally, HeLa cells are telomerase-positive, conferring unlimited replicative capacity. These molecular features create a distinct cellular environment commonly used to study cancer-relevant processes such as cell cycle deregulation and apoptosis resistance. The well-defined genetic background of HeLa cells makes them an appropriate chassis for investigating the function of uncharacterized genes like C1orf159 in transformed contexts.
C1orf159 is predicted to encode a protein, but its molecular function, interactions, and regulatory network remain entirely undefined. No upstream regulators, downstream effectors, or protein partners have been identified. The absence of characterized pathway associations makes the knockout model a critical tool for de novo functional annotation. By eliminating C1orf159 expression, researchers can systematically test its involvement in fundamental processes such as proliferation, apoptosis, migration, or stress responses. The polyclonal knockout pool allows assessment of a range of allelic disruptions, facilitating the identification of both strong and subtle phenotypes across a heterogeneous cell population.
Placing the C1orf159 knockout in the HeLa background is particularly informative due to the cell line??s reliance on HPV-driven transformation. Because p53 and Rb tumor suppressor pathways are already compromised, any phenotypic consequences of C1orf159 loss can reveal whether the gene operates in pathways that synergize with or compensate for these oncogenic disruptions. For instance, if C1orf159 normally supports growth or survival, its knockout may expose vulnerabilities in HeLa cells; conversely, if it functions as a growth suppressor, its deletion might enhance tumorigenicity. Thus, this model provides a targeted approach to uncovering context-dependent gene functions relevant to cervical cancer biology.
This knockout cell pool supports diverse research applications including functional genomics, cancer biology, phenotypic screening, and drug target validation. Compatible assays include Western blotting (when specific antibodies are available), proliferation assays (MTT/BrdU), apoptosis detection (Annexin V), cell cycle analysis, migration/invasion studies, and RNA-seq transcriptomics. These techniques enable comprehensive phenotypic profiling and downstream pathway exploration. For product inquiries and technical support, please contact Ascent Research.
